Galapagos showcases innovative approach in hematological : v

Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic...

Related Keywords

Mechelen , Region Flamande , Belgium , Glasgow , Glasgow City , United Kingdom , Eva Santermans , Mariat Kuipers , Joost Sp Vermaat , Jennifer Wilson , Marie Jos , Sophie Servais , Natalia Tovar , Kirsten Van Hoorde , Van Gijsel , Nuria Martinez Cibrian , Julio Delgado , Margotj Pont , Valentin Ortiz Maldonado , Claire Vennin , Christian Jacques , Sandra Cauwenberghs , Sandra Blum , Leticia Alserawan , Nadia Verbruggen , Martec Liefaard , Jeevan Shetty , Yves Beguin , Sergi Betriu , Kirsten Saevels , Jo Caers , Ruiz Astigarraga , Marieke Vermeersch , Stavros Milatos , Meeting Of The European Society For Blood , Head Of Clinical Development Oncology At Galapagos , Annual Meeting , European Society , Marrow Transplantation , Objective Response Rate , Complete Response , Clinical Development Oncology , Cell Therapy , Refractory Non Hodgkin Lymphoma , Maike Spoon , Oral Session , Day Vein To Point Of Care , Ana Triguero , Seven Day Vein To Point Of Care Manufactured , Cellular Therapy , Open Label Study , Evaluate Feasibility , Refractory Multiple Myeloma , Brussels Stock Exchange Glpg , Galapagos Nv ,